AACR Annual Meeting 2024

DETAILS:

ACROBiosystems is excited to meet everyone at the AACR Annual Meeting 2024 in San Diego, CA.  Come visit us at Booth #3722 and connect with our team.

We prepared cute swags including our most popular Llama Plush for you to take home!

POSTER:

Session: PO.TB05.06 - Organoid Models of Cancer 2

Title: 4245 / 16 - Selection of AAV capsids by evaluating transgene delivery using human organoid models

Date/Time: April 9, 2024, 9:00 AM - 12:30 PM

Presenter: An Ouyang, Ph.D., Product Manager

Location: Section 11

Abstract:

Recombinant adeno-associated viruses (AAVs) play a pivotal role in gene therapy, a promising approach aimed at treating various genetic disorders by introducing modified genetic material into cells or tissues. These AAV capsids are utilized as a vector in transferring genetic material into host cells. In discovery research, many AAV serotypes are developed in parallel to identify the optimal subtype for subsequent preclinical and clinical use. However, gene therapies have found limited success in clinical translation, in part, due to variable transgene delivery efficacy between traditional in vitro and in vivo models and human models. This study presents an organoid-based approach that mimics human physiology, as well as organ-specific features and cell diversity within an organ. Organoids are 3D structures derived from stem cells that resemble the cellular architecture and functionality of a specific organ. Compared to conventional 2D cell cultures, organoids provide a more comprehensive modeling of complex cell signaling, cell-cell and cell-extracellular matrix interactions, simulating the complex interplay between various cell types and functions. Within this study, several human-based organoid models were built, cerebral and cardiac, and verified by identifying the expression level of known marker genes through RNA sequencing. Five different AAV serotypes were utilized to evaluate transgene efficacy using each type of organoid model. Expression of delivered GFP transgene within each organoid was then compared to evaluate transduction and select the optimal AAV serotype in comparison to commercial wild-type AAVs. We outline the use of human organoid as an improved preclinical model for selecting AAV serotypes and evaluating transgene delivery efficacy to help provide better guidance for gene therapy development when moving into clinical research.

More about AACR 2024:  

The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting highlights the work of the best minds in cancer research from institutions all over the world.

Check out AACR 2024 Agenda HERE:

We are excited to meet everyone during Breaks and Networking Sessions! Find us at Booth #3722!